Date published: 2026-4-26

1-800-457-3801

SCBT Portrait Logo
Seach Input

Lefty Inhibitors

Lefty inhibitors belong to a distinct class of chemical compounds known for their pivotal role in regulating embryonic development and cell differentiation. These inhibitors are closely associated with the transforming growth factor-beta (TGF-β) superfamily of signaling molecules. To understand Lefty inhibitors, it's essential to appreciate their role within the intricate process of embryogenesis. During early development, Lefty inhibitors play a fundamental role in establishing the body plan of an organism. They are known for their function in maintaining symmetry and axis formation, a critical step in the early stages of embryonic development. Lefty inhibitors act as antagonists to certain signaling pathways within the TGF-β superfamily, exerting their influence by interfering with the signaling molecules involved. Specifically, they counteract the activity of Nodal, an important TGF-β member, which plays a key role in specifying the left-right axis in vertebrates. By doing so, Lefty inhibitors help ensure that the developing embryo forms with appropriate bilateral symmetry, preventing developmental abnormalities and ensuring the proper organization of vital organs.

Lefty inhibitors can be broadly classified into two isoforms: Lefty-1 and Lefty-2. Both isoforms exhibit similar mechanisms of action, working as negative regulators by binding to Nodal and inhibiting its signaling. This function is crucial for maintaining the balance of the Nodal pathway, preventing excessive or inappropriate signaling that could lead to developmental defects. Lefty inhibitors are a prime example of the delicate checks and balances that govern embryonic development. Their presence ensures the precise orchestration of signaling pathways, guaranteeing that an organism's body plan and symmetry are established correctly during its early stages of development. Understanding the mechanisms of Lefty inhibitors is not only essential for developmental biology but also holds potential implications for various fields of science and medicine, shedding light on the intricacies of cell signaling and differentiation.

SEE ALSO...

Items 1 to 10 of 15 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

BIBF1120

656247-17-5sc-364433
sc-364433A
5 mg
10 mg
$184.00
$321.00
2
(0)

Nintedanib is a tyrosine kinase inhibitor that targets multiple receptors, including VEGFR, FGFR, and PDGFR, inhibiting angiogenesis and fibrosis pathways.

Imatinib mesylate

220127-57-1sc-202180
sc-202180A
25 mg
100 mg
$45.00
$111.00
61
(1)

Imatinib inhibits the BCR-ABL tyrosine kinase, preventing aberrant signaling in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Sorafenib targets RAF and VEGFR kinases, disrupting the MAPK and VEGF pathways, which play a role in the growth and spread of cells.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$74.00
$243.00
$731.00
$2572.00
$21848.00
53
(3)

This compound broadly inhibits transcription and might reduce the expression of numerous genes, including LEFTY.

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$75.00
$121.00
33
(1)

Erlotinib inhibits the EGFR tyrosine kinase, blocking the downstream signaling pathways involved in promoting cell growth and division

Cycloheximide

66-81-9sc-3508B
sc-3508
sc-3508A
100 mg
1 g
5 g
$41.00
$84.00
$275.00
127
(6)

An inhibitor of protein translation that could reduce LEFTY protein synthesis.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Sunitinib inhibits VEGFR, PDGFR, and other kinases, interfering with angiogenesis and tumor cell proliferation, primarily used in renal cell carcinoma.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

Gefitinib is an EGFR tyrosine kinase inhibitor, halting the growth and division of cells by disrupting EGFR-driven signaling pathways.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Dasatinib targets BCR-ABL and other kinases, suppressing the proliferation of leukemia cells, mainly used for chronic myeloid leukemia (CML).

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Lapatinib is a dual EGFR and HER2 inhibitor that inhibits tyrosine kinases, hindering the growth and spread of HER2-positive breast cells.